| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3335635 | Transfusion and Apheresis Science | 2011 | 7 Pages |
IntroductionINTERCEPT treatment is used to reduce platelet transfusion associated bacterial infections. Limited data are available in Switzerland.Patients and methodsPatients with thrombocytopenia or thrombocyte dysfunction requiring platelet transfusions were enrolled in a prospective cohort study on safety (primary endpoint) and efficacy (secondary endpoint) of INTERCEPT treated platelets (I-PLTs). I-PLTs were produced from double-dose apheresis products. Data on safety were actively recorded for each transfusion.ResultsA total of 551 I-PLT units (mean platelet dose: 2.6 ± 0.4 × 1011/unit) were transfused to 46 patients (mean number of platelet transfusions per patient: 12 ± 12.5). Fifty-one (9%) transfusions were associated with adverse events and 12 (2%) with acute transfusion reactions. Eleven serious adverse events were observed, none considered as related to the administration of I-PLT. Mean 1–4 h and 16–24 h CCIs were 10.1 ± 8.1 and 3.6 ± 6.6, respectively.ConclusionThe transfusion of I-PLT was associated with a good safety profile and adequate platelet count increments at 1–4 h.
